HEART FAILURE, the most
|
|
- Edgar Page
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Aspirin and the Treatment of Heart Failure in the Elderly Harlan M. Krumholz, MD; Ya-Ting Chen, PhD; Martha J. Radford, MD Objectives: We sought (1) to determine how often aspirin is prescribed as a discharge medication among patients 65 years or older and hospitalized with both heart failure and coronary artery disease; (2) to identify patient characteristics associated with the decision to prescribe aspirin; and (3) to evaluate the association between aspirin prescription at discharge and 1-year survival. Methods: We performed a retrospective cohort study of consecutive Medicare beneficiary survivors of a hospitalization for heart failure at 18 Connecticut hospitals (up to 200 hospitalizations per hospital) from 1994 to Results: Among the 1110 patients in the study sample who did not have a contraindication to aspirin, aspirin therapy was prescribed for 456 (41%) at discharge. Patients who were prescribed aspirin at discharge had a lower 1-year mortality after discharge than patients who were not prescribed aspirin (odds ratio, 0.71; 95% confidence interval, ), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the 2 groups. Conclusions: This study has identified a strong association between the use of aspirin and lower mortality in older patients with both heart failure and coronary artery disease. The benefit of aspirin is consistent with that expected from randomized trials of other groups of patients with vascular disease. Arch Intern Med. 2001;161: From the Sections of Cardiovascular Medicine, Department of Medicine (Drs Krumholz and Radford) and Chronic Disease Epidemiology, Department of Epidemiology and Public Health (Dr Krumholz) and the Department of Medicine (Dr Chen), Yale University School of Medicine, New Haven, Conn; Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven (Drs Krumholz and Radford); and Qualidigm (formerly the Connecticut Peer Review Organization), Middletown, Conn (Drs Krumholz and Radford). Dr Chen s current affiliation is Merck and Co, Inc, West Point, Pa. HEART FAILURE, the most common discharge diagnosis among Medicare beneficiaries, is associated with a high mortality rate. Recent clinical practice guidelines have defined the best strategies for the treatment of patients with heart failure. 1-4 These guidelines, and the performance measures that have derived from them, have focused on the use of angiotensin-converting enzyme (ACE) inhibitors, digoxin, and, more recently, -blockers. Notably, aspirin has received relatively little attention for the treatment of patients with heart failure even though most of these patients have coronary artery disease. 5 Aspirin has great value for patients with coronary artery disease because of its effectiveness, low cost, safety profile, and lack of strong contraindications. Pooled analyses of more than patients with coronary artery disease show that aspirin significantly reduces longterm vascular mortality by about 20%. 6 The reluctance to endorse aspirin for patients with heart failure derives from concerns about its effects as a prostaglandin inhibitor. Aspirin is reported to attenuate the effect of antihypertensive therapy, 7-9 reduce vasodilator reserve, 10 antagonize the action of ACE inhibitors, 11 and decrease glomerular filtration pressure. 12 The clinical trials have provided relatively little information about the effect of aspirin for patients with heart failure. 13 An analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trial 14 suggested that the use of antiplatelet agents (more than 95% of which were aspirin) is associated with improved survival. The most recent heart failure guidelines warn about the combined use of antiplatelet agents and diuretics. 3-4 To address this issue, we examined the use of aspirin as a discharge medication among Medicare beneficiaries who survived a hospitalization for both heart failure and coronary artery disease. We identified patient characteristics associated with the decision to prescribe aspirin and compared the 1-year mortality of patients who were prescribed aspirin at discharge with those who were not, adjusting for baseline differences between the groups. We also evaluated the effect of aspirin among subgroups of patients by their 577
2 METHODS STUDY SAMPLE Patients for the study were identified from Medicare s national claims history file ( ) as part of a collaborative quality improvement project in Connecticut that was coordinated by Qualidigm (formerly the Connecticut Peer Review Organization), Middletown, Conn, and VHA Inc, Irving, Tex. Patients with a principal discharge diagnosis of heart failure (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes , , , , , , , , ) at 18 Connecticut hospitals from 1994 to 1995 were selected for retrospective chart review. Initially, 200 hospitalizations from each hospital were reviewed. Institutions with fewer than 200 hospitalizations had all cases reviewed. We restricted the sample to patients who were aged 65 years or older with heart failure confirmed either by symptoms of heart failure or radiographic findings consistent with the diagnosis. To decrease the heterogeneity of the sample, we excluded patients with severe aortic stenosis, severe mitral valve stenosis, or heart failure secondary to an acute medical illness (eg, sepsis). These exclusions resulted in an initial study sample of 2445 patients. For the current analysis we also excluded patients who died during hospitalization (n=169), were transferred to another institution (n=78), or had a documented terminal illness at discharge (n=37). A terminal illness was considered present if (1) a patient was documented as terminally ill or as having a life expectancy of less than 6 months; (2) the admission orders indicated that the patient should be given palliative care only; or (3) a do not resuscitate order was written. We further excluded patients who did not have an indication for aspirin use, ie, patients without coronary artery disease (n=920). Patients who had the following contraindications to long-term aspirin use were also excluded: documented allergy to aspirin (n=103), platelet count lower than /L (n=35), hematocrit level lower than 0.30 (n=274), or bleeding (n=19). The resulting sample consisted of 1110 patients. DATA SOURCE AND STUDY VARIABLES Medical Record Review Patient characteristics and clinical information (including the prescription of aspirin at discharge) were obtained from medical record review using a standardized data abstraction form. Trained nurses and medical record technicians abstracted the hospital records. Strategies to decrease abstraction errors and variability included training sessions and detailed data definitions for each field. Coronary artery disease was considered present before discharge if myocardial infarction, angina, coronary artery disease, percutaneous transluminal coronary angioplasty (PTCA), and/or coronary artery bypass graft surgery (CABG) were documented in the medical record before or during the course of hospitalization. Patients were also considered to have coronary artery disease if they were hospitalized for ischemic heart disease (ICD-9-CM codes ) in the year before the index hospitalization. Left ventricular ejection fractions (LVEFs) were obtained from medical record review based on 1 of the following 3 methods: radionuclide ventriculography, cardiac catheterization (contrast ventriculography), or echocardiography (prioritized in that order for patients in whom LVEF was measured using more than 1 method). Qualitative measures of clinical characteristics (eg, baseline renal function) and treatments (eg, ACE inhibitors). While observational studies of this type will not supplant randomized trials for establishing efficacy, they allow for the rigorous study of patients in actual clinical practice, including many patient groups that are not commonly represented in the clinical trials. RESULTS STUDY SAMPLE A total of 1110 patients who had coronary artery disease, survived a hospitalization for heart failure, and did not have a contraindication to aspirin use were included in the analysis. The sample included more women (55%) than men. The mean ±SD age was 78.3 ±7.3 years, and most patients were white (89%). Comorbidity was common in the study sample: 68% had prior heart failure; 60% had hypertension; 39% had diabetes; and 59% had a myocardial infarction before admission. Aspirin was used in 38% of the patients before the index hospitalization. The mortality at 1 year postdischarge was 24%. More than half (64%) of the patients were rehospitalized within 1 year after discharge (Table 1). PRESCRIBED USE OF ASPIRIN Aspirin was prescribed at discharge for 456 (41%) of the patients. The strongest bivariate associations (P.01) were found between aspirin prescription and hypertension; prior myocardial infarction; prior atrial fibrillation; preadmission aspirin and -blocker use; and the prescription of -blockers, digoxin, nitrates, and warfarin at discharge (Table 1). Patient and clinical characteristics independently associated with the decision to prescribe aspirin at discharge were identified using logistic regression models and stepwise selection procedures. Prior CABG; admission with chest pain; SUN level at admission; and the prescription of -blockers, calcium channel blockers, nitrates, ACE inhibitors, and warfarin at discharge were significantly associated with aspirin prescription at discharge (Table 2). Patients with a SUN level greater than mmol/l at admission and patients who were prescribed warfarin at discharge were less likely to be prescribed aspirin. Overall, the model showed a good discriminant ability (c-statistic, 0.75) in differentiating those who were and were not prescribed aspirin and did not indicate a lack of goodness of fit (P=.87). The model excluding treatments at discharge (with only demo- 578
3 left ventricular function were translated into quantitative measures as follows: normal function was assigned a value of 55% or higher; mild or mild-moderate depression, 40% to 54%; moderate or moderate-severe depression, 20% to 39%; and severe depression, lower than 20%. Missing values were indicated with a dummy variable. Other study variables included demographic characteristics (sex, age, and race); medical history (diabetes, hypertension, heart failure, myocardial infarction, angina, PTCA, CABG, atrial fibrillation, and preadmission aspirin and -blocker use); admission characteristics (blood pressure, rales, pulmonary edema on chest radiograph, potassium level, creatinine level, and albumin level); major complications during hospitalization (a composite variable including cardiac arrest, myocardial infarction, and shock); major procedures during hospitalization (a composite variable including CABG, PTCA, and cardiac catheterization); and discharge characteristics (mobility, mental status, creatinine level, ratio of serum urea nitrogen [SUN] level to creatinine level, and the prescription of -blockers, calcium channel blockers, ACE inhibitors, nitrates, nonsteroidal anti-inflammatory drugs [NSAIDs], and warfarin). Administrative Data Outcome variables (including death, all-cause readmission, heart failure related readmission, and death and readmission combined within 1 year after discharge) were obtained from administrative data. Information about readmission was derived from the Health Care Financing Administration s Medicare provider analysis and review file ( ). This file contains discharge abstracts for all Medicare inpatients from Connecticut hospitals. Information about mortality was obtained from the Medicare Enrollment Database. STATISTICAL ANALYSIS Initially, bivariate analyses were performed to examine the association between aspirin prescription and patient demographic and clinical characteristics. For presentation purposes, continuous variables were dichotomized or categorized as given in the tables. Missing data for categorical variables were considered as characteristics not present. 2 Statistics or the Fisher exact test was used to compare proportions. Multivariate logistic regression models and stepwise selection procedures with an entry level P value less than.20 and an exit level P value greater than.10 were used to identify factors independently associated with the prescription of aspirin at discharge. For these models we did not include the prescription of aspirin at admission as a predictor variable. Subsequently, associations between the prescription of aspirin and 1-year mortality postdischarge were examined. Multivariate analyses were performed using the Cox proportional hazards model, accounting for confounding effects. Assumptions of proportionality were examined and satisfied for the factors studied. Potential confounding factors were selected based on their significance in the bivariate associations with aspirin prescription and clinical judgment. The impact of aspirin use on 1-year mortality was also examined in the following subgroups: sex, age (65-74 and 75 years), presence of diabetes, creatinine level at admission ( µmol/l and µmol/l), the prescription of ACE inhibitors at discharge, the prescription of -blockers at discharge, and measures of LVEF ( 40%, 40%, and unknown). All analyses were performed using PC-SAS version 6.12 (SAS Institute Inc, Cary, NC). All P values reported were 2-sided, and a P value less than.05 was considered to indicate statistical significance. graphic and clinical variables) had much less discriminant value (c-statistic, 0.61). ASPIRIN AND MORTALITY Patients who were prescribed aspirin had a significantly lower mortality at 1 year after discharge. The association between aspirin and long-term mortality remained significant after adjusting for confounding factors including sex; age; presence of diabetes, hypertension, or prior atrial fibrillation; albumin level, SUN level, and chest pain at admission; LVEF; creatinine level and SUN/creatinine ratio at discharge; and the prescription of -blockers, calcium channel blockers, nitrates, warfarin, and ACE inhibitors at discharge (Table 3). Patients who were prescribed aspirin at discharge had a 29% lower mortality by 1 year after discharge compared with those who were not prescribed aspirin at discharge (relative risk [RR], 0.71; 95% confidence interval [CI], ). Aspirin was not associated with rates of readmission or mortality and readmission combined at 1 year after discharge (Table 1). To examine the strength of the association between aspirin and mortality, we performed subgroup analyses by sex, age, presence of diabetes, creatinine level at admission, the prescription of ACE inhibitors and -blockers at discharge, and LVEF (Table 3). In general, the beneficial effect of aspirin on mortality persisted within each subgroup, except for patients who did not receive a prescription of ACE inhibitors at discharge and patients who had a normal LVEF ( 40%). Not all of the comparisons were statistically significant, but the effect sizes were consistent. Prescriptions of other NSAIDs were found in 26 patients. An analysis combining aspirin and NSAID prescriptions did not substantially change the results. COMMENT The current American Heart Association guidelines for patients with established coronary artery disease recommend the use of aspirin. 15 This recommendation is based on the results of numerous randomized controlled trials that have indicated the efficacy of aspirin and other antiplatelet agents. 6 Despite this recommendation, the use of aspirin for patients with heart failure, many of whom have coronary artery disease, has been controversial. 13 The randomized trials for the treatment effect of aspirin generally did not report a subgroup analysis of patients with heart failure. The trials that presented data for patients with heart failure did not provide definitive results. 16,17 An analysis 579
4 Table 1. Demographics, Clinical Characteristics, and the Prescription of Aspirin at Discharge Among 1110 Patients With Both Heart Failure and Coronary Artery Disease* Aspirin Prescribed at Discharge Characteristic Patients No (n = 654) Yes (n = 456) P Demographics Sex Female 616 (55) 361 (55) 255 (56) Male 494 (45) 293 (45) 201 (44).81 Age, y (33) 223 (34) 148 (32) (45) 302 (46) 201 (44) (21) 129 (20) 107 (23) Race, nonwhite 118 (11) 77 (12) 41 (9).14 Medical history Diabetes 434 (39) 256 (39) 179 (39).93 Hypertension 671 (60) 378 (58) 293 (64).03 Heart failure 752 (68) 462 (71) 290 (64).01 Myocardial infarction 659 (59) 380 (58) 279 (61).30 Angina 387 (35) 224 (34) 163 (36).61 CABG 342 (31) 196 (30) 146 (32).47 PTCA 109 (10) 58 (9) 51 (11).21 Atrial fibrillation 302 (27) 210 (32) 92 (20).001 Aspirin use 421 (38) 126 (19) 295 (65).001 -Blocker use 299 (27) 151 (23) 148 (32).001 Admission characteristics SBP, 200 mm Hg 108 (10) 58 (9) 50 (11).25 Pulmonary edema on CR 315 (28) 171 (26) 144 (32).05 Rales basilar 682 (61) 387 (59) 295 (65).06 Chest pain 300 (27) 156 (24) 144 (32).004 Potassium level, 5 mmol/l 111 (10) 73 (11) 38 (8).12 Creatinine level, µmol/l 173 (16) 107 (16) 66 (14).39 Albumin level, 30 g/l 26 (2) 19 (3) 7 (2).28 SUN level, mmol/l 192 (17) 127 (19) 65 (14).02 Hospitalization course Major complications 41 (4) 27 (4) 14 (3).36 Major procedures 75 (7) 41 (6) 34 (7).44 LVEF, 40% No 290 (26) 175 (27) 115 (25) Yes 374 (34) 204 (31) 170 (37).10 Unknown 446 (40) 275 (42) 171 (38) Discharge characteristics Assisted mobility 220 (20) 140 (21) 80 (18).11 Confused mental status 63 (6) 41 (6) 22 (5).31 Creatinine level, µmol/l 198 (18) 118 (18) 80 (18).83 SUN/creatinine ratio, (55) 372 (57) 237 (52).11 Prescription of -blockers 254 (23) 122 (19) 132 (29).001 Prescription of calcium channel blockers 354 (32) 185 (28) 169 (37).002 Prescription of ACE inhibitors 705 (64) 408 (62) 297 (65).35 Prescription of nitrates 654 (59) 354 (54) 300 (66).001 Prescription of NSAIDs 26 (2) 19 (3) 7 (2).14 Prescription of warfarin 291 (26) 264 (40) 27 (6).001 Prescription of digoxin 652 (59) 410 (63) 242 (53).001 Outcomes, 1 y Mortality 264 (24) 174 (27) 90 (20).01 Readmission 705 (64) 419 (64) 286 (63).65 HF readmission 377 (34) 225 (34) 152 (33).71 Mortality or readmission 779 (70) 470 (72) 309 (68).14 *Unless otherwise indicated, data are number (percentage) of patients. CABG indicates coronary artery bypass graft surgery; PTCA, percutaneous transluminal coronary angioplasty; SBP, systolic blood pressure; CR, chest radiograph; SUN, serum urea nitrogen; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs; and HF, heart failure. of a randomized trial population of patients with heart failure suggested that there is a benefit in using the medication. 14 Physiology-based studies have provided a rationale for a potential harm of inhibiting prostaglandins in these patients. As a result, guidelines do not endorse the use of aspirin for patients with heart failure, even for those with coronary artery disease. This uncertainty seems to have affected practice. In our study, among the patients who had coronary artery disease and did not have a contraindication to aspirin, only 580
5 41% were prescribed aspirin at discharge, which goes against the recommendations of the American Heart Association s secondary prevention guidelines. 15 Patients who were less likely to be prescribed aspirin included those with a history of atrial fibrillation and a high SUN level at admission. However, demographic and clinical characteristics provided relatively little information about the decision to prescribe aspirin, suggesting that there is great variability in practice that is not dictated by the patient s condition. The benefit associated with aspirin in this study was substantial. Overall, patients who were prescribed aspirin at discharge had a 29% lower risk of mortality at 1 year than the other patients. This reduction of risk among patients with heart failure is comparable to that reported in the randomized trials of patients with vascular disease. 6 The benefit demonstrated in our results is also remarkably close to that estimated from the patients enrolled in the SOLVD trial. 14 Given the high risk Table 2. Predictors of Aspirin Presciption at Discharge* Factor AOR 95% CI P Prior CABG 1.63 ( ).002 Chest pain at admission 1.38 ( ).04 SUN level, mmol/l at admission 0.67 ( ).03 Prescription of -blockers at discharge 1.90 ( ).001 Prescription of calcium 1.47 ( ).01 channel blockers at discharge Prescription of nitrates at discharge 1.46 ( ).01 Prescription of ACE inhibitors 1.52 ( ).01 at discharge Prescription of warfarin at discharge 0.08 ( ).001 *AOR indicates adjusted odds ratio; CI, confidence interval; CABG, coronary artery bypass graft surgery; SUN, serum urea nitrogen; and ACE, angiotensin-converting enzyme. Adjusted odds ratios are based on logistic regression model adjusting for other factors in the model. of mortality among patients with heart failure, this relative reduction in mortality translates into a benefit of 60 lives saved per 1000 patients treated. This estimate compares with the results of the trials that found antiplatelet therapy to be associated with about 40 vascular events avoided for every 1000 patients treated. In exploratory analyses, we examined potential interactions of aspirin with other patient characteristics and treatments. In general, we found a consistent effect across subgroups. In some cases, the effect was not statistically significant, but the effect size was similar to other groups and the overall result. Studies have suggested that aspirin may interfere with the beneficial effects of ACE inhibitors In patients with reduced LVEF, the SOLVD trial found that antiplatelet agents reduced the benefit from enalapril in the treatment trial but not in the prevention trial. The investigators concluded that antiplatelet agents were associated with a persistent though reduced benefit from enalapril. 14 We found that aspirin was associated with a greater survival advantage among patients who were prescribed ACE inhibitors, as well as those with a reduced LVEF. We did not specifically examine the influence of aspirin on the benefit of ACE inhibitors because that would require restricting the sample to ideal candidates for ACE inhibitors, which would markedly reduce the power of the study. Future studies clearly need to address directly whether there are specific groups that do not benefit from aspirin use or in which aspirin antagonizes ACE inhibitors. We also were not able to assess the combined effect of aspirin and warfarin because so few patients were treated with both medications. The study has several limitations. First, treatment was not randomly allocated. However, our methods minimized the problems in drawing inferences from observational data. 22 We defined a cohort of patients who had coronary artery disease and were free of contraindications to Table 3. Prescription of Aspirin at Discharge and 1-Year Mortality* Deaths, No. (%) Without Aspirin Use With Aspirin Use ARR 95% CI P Overall 174 (27) 90 (20) 0.71 ( ).02 Male 82 (28) 48 (24) 0.79 ( ).26 Female 92 (25) 42 (16) 0.65 ( ).03 Aged y 43 (19) 18 (12) 0.59 ( ).09 Aged 75 y 131 (30) 72 (23) 0.78 ( ).13 No diabetes 108 (27) 56 (20) 0.64 ( ).01 Diabetes 66 (26) 34 (19) 0.90 ( ).65 Creatinine level, µmol/l 133 (24) 72 (18) 0.73 ( ).04 Creatinine level, µmol/l 41 (38) 18 (27) 0.56 ( ).07 ACE-I not prescribed at discharge 60 (24) 40 (25) 1.20 ( ).43 ACE-I prescribed at discharge 114 (28) 50 (17) 0.54 ( ).001 -Blockers not prescribed at discharge 146 (27) 64 (20) 0.67 ( ).01 -Blockers prescribed at discharge 28 (23) 26 (20) 0.77 ( ).40 LVEF, 40% 35 (20) 25 (22) 1.10 ( ).76 LVEF, 40% 52 (25) 25 (15) 0.51 ( ).01 LVEF unknown 87 (32) 40 (23) 0.72 ( ).13 *ARR indicates adjusted risk ratio; CI, confidence interval; ACE-I, angiotensin-converting enzyme inhibitor; and LVEF, left ventricular ejection fraction. Adjusted risk ratios are based on Cox proportional hazards models adjusting for sex; age; prior atrial fibrillation, diabetes, hypertension; albumin and serum urea nitrogen (SUN levels at admission; LVEF; chest pain at admission; creatinine level at discharge; SUN/creatinine ratio at discharge; and the prescriptions of -blockers, calcium channel blockers, nitrates, warfarin, and ACE-I at discharge (except when the factor is used for stratification). 581
6 aspirin. We designated discharge as the reference time at which baseline clinical status was determined and from which follow-up was ascertained. We collected detailed information to adjust for differences between the treatment groups in their risk of mortality. While we cannot exclude the possibility of residual confounding factors, our results are very close to what was reported from randomized trials of patients with cardiovascular disease. Second, we focused on patients who were aged 65 years or older in Connecticut, and the generalizability of our findings to younger patients is not known. Nevertheless, our study is relevant to more than 80% of the patients hospitalized in the United States with heart failure and who are Medicare beneficiaries. Moreover, our sample was not selected and represents the patients who are seen in practice. The study, however, was conducted solely in Connecticut, which has a high rate of aspirin use among patients discharged after an acute myocardial infarction compared with the rest of the country. 23 Consequently, our estimates of the use of aspirin for patients with heart failure may be higher than what might be found in other regions, and the opportunity to improve care may be even greater elsewhere. Third, we ascertained the use of aspirin at discharge through retrospective chart review. It is possible that aspirin use may not have been properly recorded or that treatment may not have continued after hospital discharge. These limitations, however, would have tended to diminish the association between aspirin use and improved survival. Fourth, we determined the presence of coronary artery disease based on information from medical records. This method may have led to some misclassification of patients. The inclusion of patients in our cohort who did not have coronary artery disease would have tended to dilute the effect of aspirin unless it is effective for heart failure that is caused by nonischemic factors. Finally, we are limited in our ability to suggest a mechanism of the benefit. We did not find a difference in the all-cause readmission rate or the heart failure readmission rate. The analysis from the SOLVD trial found that the reduction in mortality from antiplatelet agents was due to a reduction in sudden death and a reduction in fatal myocardial infarction. No association was found between antiplatelet agents and death associated with worsening heart failure. 14 In conclusion, this study, undertaken as part of a local effort to improve care for Medicare beneficiaries with heart failure, identified a strong association between the use of aspirin and lower mortality among patients with both heart failure and coronary artery disease. The benefit of aspirin is consistent with what would be expected from randomized trials of other groups of patients with vascular disease. None of the analyses suggested that aspirin was associated with a significant harm. Thus, increasing the use of aspirin at discharge may be an excellent opportunity to improve the care of elderly patients with heart failure. Further studies need to determine the impact of aspirin on the benefit of ACE inhibitors. Accepted for publication August 31, Reprints: Harlan M. Krumholz, MD, Yale University School of Medicine, 333 Cedar St, PO Box , New Haven, CT ( REFERENCES 1. ACC/AHA Task Force. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;92: Konstam MA, Dracup K, Baker DW, et al. Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services; Clinical Practice Guideline No Packer M, Cohn JN, for the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999; 83:2A-38A. 4. Adams KF Jr for the Heart Failure Society of America Guideline Committee. HFSA practice guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Fail. 1999; 5: Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88: Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991;90:S42-S Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? a meta-analysis. Ann Intern Med. 1994;121: Oates JA. Antagonism of antihypertensive drug-therapy by nonsteroidal antiinflammatory drugs. Hypertension. 1988;11(pt 2): Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the reninangiotensin system and hyponatremia. N Engl J Med. 1984;310: Hall D, Zeitler J, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20: Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med. 1991; 90: Cleland JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J. 1995;74: Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31: Smith SC Jr, Blair SN, Criqui MH, et al. Consensus panel statement: preventing heart attack and death in patients with coronary disease. Circulation. 1995;92: Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980; 243: The Persantine-Aspirin Reinfarction Study (PARIS) Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980;62: Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997; 79: Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med. 1992;327: Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol. 1993;22(suppl A):158A-161A. 21. Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensinconverting enzyme inhibitors. Am Heart J. 1999;138: Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med. 1990;89: O Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA. 1999;281:
ORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction Harlan M. Krumholz, MD; Ya-Ting Chen, PhD; Yongfei
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationAspirin, Beta-Blocker, and Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With End-Stage Renal Disease and an Acute Myocardial Infarction
Journal of the American College of Cardiology Vol. 42, No. 2, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00572-2
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationRandomized trials have established the efficacy of ACE
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction Frederick A. Masoudi, MD, MSPH; Saif
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationOutcomes in Heart Failure Patients With Preserved Ejection Fraction Mortality, Readmission, and Functional Decline
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00185-2
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationPOSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)
POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002) Well designed, large scale, randomized double-blind, placebo-controlled trials have validated the efficacy of the ACE-inhibitor enalapril in
More informationTHERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%
Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction
More informationPopulations Interventions Comparators Outcomes Individuals: With diagnosed heart disease. rehabilitation
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 01/01/17 Next Review Date: 05/18 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More informationDoes quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?
Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)? Erika Friedmann a, Eleanor Schron, b Sue A. Thomas a a University of Maryland School of Nursing; b NEI, National
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationMYOCARDIAL INFARCTION
360 MYOCARDIAL INFARCTION Use of Angiotensin-Converting Enzyme Inhibitors at Discharge in Patients With Acute Myocardial Infarction in the United States: Data From the National Registry of Myocardial Infarction
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationORIGINAL INVESTIGATION. Profile for Estimating Risk of Heart Failure
ORIGINAL INVESTIGATION Profile for Estimating Risk of Heart Failure William B. Kannel, MD, MPH; Ralph B. D Agostino, PhD; Halit Silbershatz, PhD; Albert J. Belanger, MS; Peter W. F. Wilson, MD; Daniel
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationBackground- Methods and Results- Conclusion-
Patterns of Use of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE Retrospective AMI Study
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Heart Failure (HF) Set Measure ID#: HF-1 Measure Information Form Performance
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationDespite declining age-adjusted incidence and mortality
Sex Differences in the Prognosis of Congestive Heart Failure Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) Tabassome Simon, MD; Murielle Mary-Krause, PhD; Christian Funck-Brentano,
More informationORIGINAL INVESTIGATION. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure
Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure Results From the ATLAS Trial ORIGINAL INVESTIGATION Barry M. Massie, MD; Paul W. Armstrong, MD;
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationn Kristensen, S. L., Jhund, P. S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F., Carson, P. E., and McMurray, J. J.V. (2015) Relative importance of history of heart
More informationCLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More informationMeasurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationJournal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00675-5 Beta-Adrenergic
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationUse of evidence-based therapies after discharge among elderly patients with acute myocardial infarction
CMAJ Research Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction Peter C. Austin PhD, Jack V. Tu MD PhD, Dennis T. Ko MD MSc, David A. Alter MD PhD
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationCORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
More informationAttendance rates and outcomes of cardiac rehabilitation in Victoria, 1998
Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998 CARDIOVASCULAR DISEASE is the leading cause of death in Australia, causing more than 40% of all deaths in 1998. 1 Cardiac rehabilitation
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationDiagnostic, Technical and Medical
Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX Background
More informationOutpatient Utilization of Angiotensin- Converting Enzyme Inhibitors Among Heart Failure Patients After Hospital Discharge
Journal of the American College of Cardiology Vol. 43, No. 11, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.041
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationLeft ventricular end-diastolic pressure
www.lejacq.com ID:6624 O R I G I N A L P A P E R Left Ventricular End-Diastolic Pressure and Risk of Subsequent Heart Failure in Patients Following an Acute Myocardial Infarction Left ventricular end-diastolic
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationTable 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings
CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationThe American Experience
The American Experience Jay F. Piccirillo, MD, FACS, CPI Department of Otolaryngology Washington University School of Medicine St. Louis, Missouri, USA Acknowledgement Dorina Kallogjeri, MD, MPH- Senior
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationAcute myocardial infarction. Cardiovascular disorders. main/0202_new 02/03/06. Search date August 2004 Nicholas Danchin and Eric Durand
main/0202_new 02/03/06 Acute myocardial infarction Search date August 2004 Nicholas Danchin and Eric Durand QUESTIONS Which treatments improve outcomes in acute myocardial infarction?...4 Which treatments
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More information